Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation

Journal of Immunotherapy

Volumn 36, Issue 4, 2013, Pages 248-257

  Dai, Min ^a   Wei, Huafeng ^b   Yip, Yuen Yee ^a   Feng, Qinghua ^a   He, Kecheng ^b   Popov, Viorica ^a   Hellstrom, Ingegerd ^a   Hellstrom, Karl Erik ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD137; CD19; CTLA4; inflammation; melanoma; ovarian carcinoma; PD 1

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; DENDRITIC CELL; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; MELANOMA; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SUPPRESSOR CELL; TH2 CELL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTIGENS, CD19; ANTIGENS, DIFFERENTIATION; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; GENE EXPRESSION PROFILING; IMMUNOPHENOTYPING; INFLAMMATION; LYMPHOCYTE DEPLETION; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; PHENOTYPE; TH1 CELLS; TH2 CELLS;

EID: 84876808236     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182943549     Document Type: Article

References (51)

1. Hellstrom KE, Hellstrom I. Cellular immunity against tumor specific antigens. Adv Cancer Res. 1969;12:167-223.
2. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12: 337-365. (Pubitemid 24140418)
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384. (Pubitemid 32467048)
4. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545. (Pubitemid 32173595)
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867. (Pubitemid 36019639)
6. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
7. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91-102.
8. Feng Q, Wei H, Morihara J, et al. Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol. 2012;127:412-419.
9. Kwon BS, Tan KB, Ni J, et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J Biol Chem. 1997;272:14272-14276. (Pubitemid 27232840)
10. Kim YJ, Kim SH, Mantel P, et al. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol. 1998;28:881-890. (Pubitemid 28116201)
11. Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343-348. (Pubitemid 34407028)
12. Melero I, Johnston JV, Shufford WW, et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190:167-172. (Pubitemid 29011104)
13. Mittler RS, Bailey TS, Klussman K, et al. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med. 1999;190:1535-1540.
14. Ammirante M, Luo JL, Grivennikov S, et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302-305.
15. Topalian SL, Hodi S, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med. 2012;366:2443-2454.
16. Flies DB, Sandler B, Sznol M, et al. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med. 2011;84:409-421.
17. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65:1089-1096. (Pubitemid 40216472)
18. Ascierto P, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37:508-516.
19. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271: 1734-1736. (Pubitemid 26102823)
20. + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184:4006-4016.
21. Fransen MF, Sluijter M, Morreau H, et al. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17:2270-2280.
22. Curran M, Kim MR, Montalvo W, et al. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation and cytokine production. PloS One. 2011;6:e19499.
23. Price JE, Tarin D, Fidler I. Influence of organ microenvironment on pigmentation of a metastatic murine melanoma. Cancer Res. 1988;48:2258-2264.
24. Yang SC, Yang Y, Raycraft J, et al. Melanoma cells transfected to express CD83 induce anti-tumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci. 2004;101:4990-4995. (Pubitemid 38469190)
25. Liu P, Jaffar J, Zhou J, et al. Inhibition of TGFbeta 1 makes nonimmunogenic tumor cells effective for therapeutic vaccination. J. Immunother. 2009;32:232-239.
26. de Visser K, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37. (Pubitemid 43053650)
27. de Visser KE, Korets LV, Coussens LM. De novo carcino-genesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell. 2005;7:411-423. (Pubitemid 40719125)
28. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585-591. (Pubitemid 30214011)
29. Fidler IJ, Gersten DM, Budmen MB. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res. 1976;36:3160-3165.
30. Tuve S, Liu Y, Tragoolpua K, et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine. 2009;27:4225-4239.
31. Liu P, Jaffar J, Hellstrom I, et al. Administration of cyclophosphamide changes the immune profile of tumor-bearing mice. J. Immunother. 2010;33:53-59.
32. Hung CF, Tsai Y, He L, et al. Controll of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin-peptide specific CD8 T cells. Gene Ther. 2007;14:921-929. (Pubitemid 46865503)
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
34. Ovestad IT, Gudlaugsson E, Skaland I, et al. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol. 2010;23:1231-1240.
35. Liu Y, Tuve S, Persson J, et al. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther. 2011;18:407-418.
36. Zou W. Regulatory T cells, tumour immunity and immuno-therapy. Nat Rev Immunol. 2006;6:295-307.
37. Talmadge JE. Pathways mediating the expansion and immuno-suppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13:5243-5248. (Pubitemid 47510346)
38. Gilboa E. The risk fof autoimmunity associated with tumor immunotherapy. Nat Immunol. 2001;2:789-792.
39. Rickert R, Rajewsky K, Roes J. Impairment of T-cell dependent B-cell responses and B-1 cell development in CD19 deficient mice. Nature. 1995;376:352-355.
40. Legler D, Loetscher M, Roos R, et al. B cell-attrracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attaracts b lymphocytes via aBLR1/CXCR5. J Exp Med. 1998;187:655-660. (Pubitemid 28093368)
41. Ammirante M, Luo J, Grivennikov S, et al. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;11:302-305.
42. Messina JL, Fenstermacher DA, Eschrich S, et al. 12-Chemo-kine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep. 2012;2:765.
43. Hellstrom I, Hellstrom KE, Evans CA, et al. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci USA. 1969;62:362-368.
44. Sjogren HO, Hellstrom I, Bansal SC, et al. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci USA. 1971;68:1372-1375.
45. Baldwin RW, Price MR, Robins RA. Blocking of lyimphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nature. 1972;238:185-187.
46. Hellstrom KE, Hellstrom I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974;18:209-277.
47. Moller G. Effect on tumor growth in syngeneic recipients of antibodies against tumor-specific antigens in methylcholan-threne-induced mouse sarcomas. Nature. 1964;204:846-847.
48. Andreu P, Johansson M, Affara NI, et al. FcRgamma activation regulates inflammation-associated squamous carci-nogenesis. Cancer Cell. 2010;17:121-134.
49. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of antitumor CTL and TH1 cytokine responses by B cells. Int J Cancer. 2005;117:574-586. (Pubitemid 41504545)
50. Kim S, Fridlender ZG, Dunn R, et al. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother. 2008;31:446-457.
51. Lei C, Liu P, Chen B, et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J AmChem Soc. 2010;132:6906-6907.